1
|
Makhija S, Griffett JD, Veerakanellore GB, Burris TP, Elgendy B, Griffett K. REV-ERB activation as a novel pharmacological approach for treating inflammatory pain. Front Pharmacol 2023; 14:1171931. [PMID: 37153791 PMCID: PMC10154555 DOI: 10.3389/fphar.2023.1171931] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2023] [Accepted: 04/04/2023] [Indexed: 05/10/2023] Open
Abstract
Pain is a complex problem affecting millions of people worldwide. The current therapies to reduce pain are limited as many treatment options inadequately address the causes of pain, lead to tolerance of the drug, or have adverse effects including abuse potential. While there are many causes of pain, one underlying mechanism to the pathogenesis and maintenance of pain conditions is chronic inflammation driven by the NLRP3 inflammasome. Several inflammasome inhibitors are currently under investigation however have the potential to suppress the functioning of the innate immune system, which may cause unwanted affects in patients. Here, we show that the nuclear receptor REV-ERB can suppress the activation of the inflammasome when pharmacologically activated with small molecule agonists. Additionally, REV-ERB activation appears to have analgesic potential in a model of acute inflammatory pain, likely as a result of inflammasome suppression.
Collapse
Affiliation(s)
- Sangeet Makhija
- Department of Anatomy, Physiology, and Pharmacology, College of Veterinary Medicine, Auburn University, Auburn, AL, United States
| | - Joshua D. Griffett
- Department of Anatomy, Physiology, and Pharmacology, College of Veterinary Medicine, Auburn University, Auburn, AL, United States
| | - Giri Babu Veerakanellore
- Center for Clinical Pharmacology, Washington University School of Medicine, University of Health Sciences & Pharmacy, St. Louis, MO, United States
- Department of Pharmaceutical and Administrative Sciences, University of Health Sciences & Pharmacy, St. Louis, MO, United States
| | - Thomas P. Burris
- University of Florida Genetics Institute, Gainesville, FL, United States
| | - Bahaa Elgendy
- Center for Clinical Pharmacology, Washington University School of Medicine, University of Health Sciences & Pharmacy, St. Louis, MO, United States
- Department of Pharmaceutical and Administrative Sciences, University of Health Sciences & Pharmacy, St. Louis, MO, United States
| | - Kristine Griffett
- Department of Anatomy, Physiology, and Pharmacology, College of Veterinary Medicine, Auburn University, Auburn, AL, United States
| |
Collapse
|
2
|
XIE YONGGANG, MU HONGJIE, LI ZHEN, MA JIAHAI, WANG YUELAN. Supression of chronic central pain by superoxide dismutase in rats with spinal cord injury: Inhibition of the NMDA receptor implicated. Exp Ther Med 2014; 8:1137-1141. [PMID: 25187811 PMCID: PMC4151704 DOI: 10.3892/etm.2014.1878] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/01/2014] [Accepted: 05/14/2014] [Indexed: 12/16/2022] Open
Abstract
Superoxide dismutase (SOD) is used to manage chronic pain, including neuropathic and inflammatory pain. However, data regarding the clinical effectiveness are conflicting and the neurophysiological mechanism of SOD has yet to be elucidated. The aim of the present study was to investigate whether SOD relieved chronic central pain (CCP) following spinal cord injury (SCI) and the possible underlying mechanisms. A CCP model was established using the Allen method and the CCP of the rats was measured using the paw withdrawal threshold. SOD was administered intraperitoneally following the establishment of CCP as a result of SCI. The results demonstrated that SOD relieved CCP in rats following SCI. In addition, the expression of spinal phosphorylated N-methyl-D-aspartate(NMDA) receptor subunit 1 (pNR-1) was inhibited in the CCP rats that had been treated with SOD. These observations indicated that SOD reduced mechanical allodynia and attenuated the enhancement of spinal pNR1 expression in rats with CCP. In addition, the results indicated that superoxide, produced via xanthine oxidase, and the participation of superoxide and nitric oxide (NO) as a precursor of peroxynitrite in NMDA, were involved in the mediation of central sensitization. Therefore, the observations support the hypothesis that SOD may have a potential therapeutic role for the treatment of CCP following SCI via the manipulation of superoxide and NO.
Collapse
Affiliation(s)
- YONG-GANG XIE
- Department of Anesthesiology, Qianfoshan Hospital, Affiliated to Shandong University Medical College, Jinan, Shandong 250014, P.R. China
- Department of Anesthesiology, Yuhuangding Hospital Affiliated to Qingdao University Medical College, Yantai, Shandong 264000, P.R. China
| | - HONG-JIE MU
- Department of Orthopedics, Yantaishan Hospital Affiliated to Medical College of Taishan, Yantai, Shandong 264000, P.R. China
| | - ZHEN LI
- Department of Otorhinolaryngology, Yantaishan Hospital Affiliated to Medical College of Taishan, Yantai, Shandong 264000, P.R. China
| | - JIA-HAI MA
- Department of Anesthesiology, Yuhuangding Hospital Affiliated to Qingdao University Medical College, Yantai, Shandong 264000, P.R. China
| | - YUE-LAN WANG
- Department of Anesthesiology, Qianfoshan Hospital, Affiliated to Shandong University Medical College, Jinan, Shandong 250014, P.R. China
| |
Collapse
|
3
|
Miskimon M, Han S, Lee JJ, Ringkamp M, Wilson MA, Petralia RS, Dong X, Worley PF, Baraban JM, Reti IM. Selective expression of Narp in primary nociceptive neurons: role in microglia/macrophage activation following nerve injury. J Neuroimmunol 2014; 274:86-95. [PMID: 25005116 DOI: 10.1016/j.jneuroim.2014.06.016] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2013] [Revised: 05/13/2014] [Accepted: 06/19/2014] [Indexed: 11/19/2022]
Abstract
Neuronal activity regulated pentraxin (Narp) is a secreted protein implicated in regulating synaptic plasticity via its association with the extracellular surface of AMPA receptors. We found robust Narp immunostaining in dorsal root ganglia (DRG) that is largely restricted to small diameter neurons, and in the superficial layers of the dorsal horn of the spinal cord. In double staining studies of DRG, we found that Narp is expressed in both IB4- and CGRP-positive neurons, markers of distinct populations of nociceptive neurons. Although a panel of standard pain behavioral assays were unaffected by Narp deletion, we found that Narp knockout mice displayed an exaggerated microglia/macrophage response in the dorsal horn of the spinal cord to sciatic nerve transection 3days after surgery compared with wild type mice. As other members of the pentraxin family have been implicated in regulating innate immunity, these findings suggest that Narp, and perhaps other neuronal pentraxins, also regulate inflammation in the nervous system.
Collapse
Affiliation(s)
- M Miskimon
- Department of Neuroscience, Johns Hopkins University, United States
| | - S Han
- Department of Psychiatry, Johns Hopkins University, United States
| | - J J Lee
- Department of Psychiatry, Johns Hopkins University, United States
| | - M Ringkamp
- Department of Neurosurgery, Johns Hopkins University, United States
| | - M A Wilson
- Department of Neuroscience, Johns Hopkins University, United States
| | - R S Petralia
- NIDCD, NIH, Johns Hopkins University, United States
| | - X Dong
- Department of Neuroscience, Johns Hopkins University, United States
| | - P F Worley
- Department of Neuroscience, Johns Hopkins University, United States
| | - J M Baraban
- Department of Neuroscience, Johns Hopkins University, United States; Department of Psychiatry, Johns Hopkins University, United States
| | - I M Reti
- Department of Neuroscience, Johns Hopkins University, United States; Department of Psychiatry, Johns Hopkins University, United States; Laboratory of Origin, United States.
| |
Collapse
|
4
|
Abstract
Earlier, we had reported that co-administration of opioids and L-type calcium channel blockers (L-CCBs) like diltiazem could prove useful in the treatment of cancer pain. Much of this report was based upon earlier published work involving animal models of pain exposed to brief periods of noxious radiant heat without any tissue injury. However, pain in clinical situations usually result from tissue injury. Thus, the aim of the current investigation was to study the analgesic effect of this combination of drugs in the rat formalin test which is associated with actual tissue injury. Wistar rats (n=60) received either L-CCB (nifedipine/nimodipine/verapamil/diltiazem i.p.) or morphine (s.c.) or both drugs. The formalin test was done 30 min after morphine or placebo injection. The naloxone reversal test was also done. Administration of L-CCBs alone, particularly diltiazem, increased pain in the formalin test. In contrast, co-administration of these L-CCBs with morphine led to decreased pain response, though statistically significant decrease was noted only with nimodipine + morphine. Naloxone reversed this analgesic effect, indicating that it was primarily an opioid-mediated effect. The results show that administration of L-CCBs alone may prove counterproductive in the therapeutic management of pain (anti-analgesic effect). However, co-administration of both drugs (morphine and nimodipine) in quick succession could lead to adequate pain relief.
Collapse
Affiliation(s)
- Rakesh Kumar
- Department of Anatomy, All India Institute of Medical Sciences, New Delhi - 110 029, India
| | | | | |
Collapse
|